Preparation of aryl intermediates
Granted 4 Apr 2006 · no office action yet
Current assignee: Boehringer Ingelheim Pharmaceuticals · originally Boehringer Ingelheim International GmbH
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Zhulin Tan, Nathan K. Yee, Jinhua J. Song · Examiner: Taofiq Solola · AU 1626 · TC 1600
Life of the application
7 dated eventsAbstract
Disclosed are methods of making aryl intermediate compounds of the formula (A) which are useful in the production of heteroaryl ureas, [structure] Y and P are defined herein below.
Description
6 parts›APPLICATION DATA
This application claims benefit to U.S. provisional application No. 60/428,618 filed Nov. 22, 2002.
›FIELD OF INVENTION
This invention relates to the synthesis of aryl intermediate compounds which are useful in the production of pharmaceutically active heteroaryl urea compounds.
›BACKGROUND OF THE INVENTION
Aryl- and heteroaryl-substituted ureas have been described as inhibitors of cytokine production. These inhibitors are described as effective therapeutics in cytokine-mediated diseases, including inflammatory and autoimmune diseases.
U.S. Pat. No. 6,358,945 describes cytokine inhibiting ureas of the following formula:
An intermediate required to prepare preferred compounds described therein has a 1,4-disubstituted naphthalene as Ar 2 and is illustrated in the formula below.
The preparation of these intermediates require the coupling of the naphthyl ring with X. Preferred X include aryl and heteroaryl groups. Previously described methods, including U.S. Pat. No. 6,358,945 achieves the coupling of these aromatic residues by using a coupling reaction catalyzed by a transition metal, such as palladium, in the presence of a ligand, such as triphenyl phosphine. Coupling methods include Stille coupling, requiring the preparation of a tributylstannyl intermediate, or a Suzuki coupling, requiring the preparation of an aryl boronic acid intermediate (Scheme I).
The aryl boronic acid intermediate shown in I has previously been prepared via Br—Li exchange at −70° C. It is desirable to develop a procedure without using cryogenic condition for large-scale or industrial scale production.
Kitigawa et al. disclose a method for preparing trialkyl magnesates useful for halogen-metal exchange ( Angew. Chem. Int. Ed. 2000, 39, No. 14 2481–2483). No example in the paper implied the applicability of this method to the preparation of A, which has an acidic proton on the nitrogen.
›BRIEF SUMMARY OF THE INVENTION
It is therefore an object of the invention to provide a non-cryogenic synthesis for aryl intermediate compounds such as aryl boronic acids which are useful in the production of heteroaryl urea compounds.
›DETAILED DESCRIPTION OF THE INVENTION
In a broad generic aspect, there is provided a method of making a compound of the formula (A):
wherein the formula (A):
P is a nitrogen protecting group compatible with Grignard reagents, preferably P is chosen from Boc, Cbz, —CO 2 Me, —Ac, -Bn; preferably P is Boc;
Y is chosen from —B(OH) 2 , —CHR′—OH, —CR′ 2 —OH, alkyl, alkene and acyl;
E is an electrophile as defined herein below;
the phenyl ring in (A) is optionally benzo-fused to form naphthyl wherein substituents Y or NH—P can be independently at any position on each of the one or two rings, where the phenyl is not benzo-fused substitution can be para, meta or ortho, preferably para; preferably formula (A) is
said method comprising, in a one pot reaction:
reacting a compound of the formula (B) with 2 equivalents of R 3 MgLi, wherein and R is C 1-5 alkyl, preferably n-butyl, in an aprotic solvent at a temperature between −40° C. to 40° C., preferably −20° C. to 0° C., more preferably 0° C., the aprotic solvent is, for example, dioxane, diethoxymethane, methylTHF, THF, diisopropylether, hydrocarbons including hexanes, heptane, isooctane, cyclohexane, xylenes, Toluene, dichloromethane, DME, MTBE, or mixtures thereof, preferably the aprotic solvent is THF;
wherein X is bromine or iodine, preferably bromine, subsequently adding an electrophile E, such as, for example, B(OCH 3 ) 3 , aldehydes such as CH 3 CHO, ArylCHO, ketones such as CH 3 COCH 3 , ArylCOCH 3 , halide such as CH 2 ═CHCH 2 Br, CH 3 I, or esters such as CH 3 CO 2 Et, preferably E is B(OCH 3 ) 3 , further non-limiting examples of E are set forth in the table below;
to produce a compound of the formula (A)
All terms as used herein in this specification, unless otherwise stated, shall be understood in their ordinary meaning as known in the art.
RT or rt—room temperature;
n-BuLi—n-Butyllithium
DME—1,2-Dimethoxyethane
THF—Tetrahydrofuran.
Boc—tert-Butoxycarbonyl.
Cbz—Benzyloxycarbonyl.
Ac—Acetyl.
Bn—Benzyl.
MeLi—methyllithium.
Unless otherwise noted, alkyl shall be understood to mean C 1-10 alkyl chain, preferably C 1-5 alkyl, branched or unbranched. An alkene is a partially unsaturated alkyl.
Ester, acyl, ketone, aldehyde and alkene shall be understood to mean an alkyl chain as herein above defined, with the respective functional group.
The term “aryl” as used herein shall be understood to mean aromatic carbocycle or heteroaryl as defined herein. Preferred carbocycles include phenyl and naphthyl. Each aryl or heteroaryl unless otherwise specified includes it's partially or fully hydrogenated derivative. For example, naphthyl may include it's hydrogenated derivatives such as tetrahydranaphthyl. Other partially or fully hydrogenated derivatives of the aryl and heteroaryl compounds described herein will be apparent to one of ordinary skill in the art.
It shall be understood, that the definitions E and Y have the following corresponding relationship as seen in the table and scheme below:
Wherein R′ can be alkyl or aryl as defined herein, X is halogen and for B(O—C 1-5 alkyl) 3 the C 1-5 alkyl includes all C 1-5 alkyl, preferably methyl, ethyl, propyl and butyl, more preferably methyl.
The compounds of the invention are only those which are contemplated to be ‘chemically stable’ as will be appreciated by those skilled in the art. For example, a compound which would have a ‘dangling valency’, or a ‘carbanion’ are not compounds contemplated by the invention.
In order that this invention be more fully understood, the following examples are set forth in the overall reaction scheme below. These examples are for the purpose of illustrating preferred embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.
›EXAMPLE
Synthesis of N-Boc-4-amino-1-naphthalene Boronic Acid
In a dry flask under Argon was added butylmagnesium chloride (2.0 M in THF, 2.0 mL, 4.0 mmol) and anhydrous THF (10 mL). The solution was cooled to −5° C. and butyllithium (1.6 M in hexane, 5.0 mL, 8.0 mmol) was added dropwise while the temperature was kept below 0° C. After the resulting solution was stirred at 0° C. for 0.5 h, the temperature was lowered to −5° C. N-Boc-4-bromo-1-aminonaphthalene (0.64 g, 2.0 mmol) was dissolved in anhydrous THF(10 mL) and added dropwise while the temperature was kept below 0° C. The solution was stirred at 0° C. for 0.5 h. HPLC of a sample taken from the solution and quenched with MeOH indicated that no starting material was left. The temperature was lowered to −5° C. and trimethyl borate(2.5 mL, 22.0 mmol) was added slowly. After the mixture was stirred at 0° C. for 2 h, ammonium chloride solution (saturated, 20 mL) was added and the mixture was stirred at 21° C. for 0.5 h. The pH of the mixture was adjusted to 7 with sodium bicarbonate and the mixture was stirred at 21° C. for 18 h. Ethyl acetate (10 mL) was added and the mixture was stirred for 0.5 h. The organic layer was separated and dried with magnesium sulfate. The solvent was removed under vacuum and then hexane (60 mL) was added and the resulting slurry was stirred for 0.5 h. Filtration and hexane (10 mL) wash gave the title compound as a white solid (0.46 g, 80.5% pure, 65% yield).
›Tables in the description — 1
| E | Y |
| B(O—C 1–5 alkyl) 3 | —B(OH) 2 |
| R′HC═O | —CHR′—OH |
| R′ 2 C(═O) | —CR′2—OH |
| R′X | —R′ |
| R′CO 2 R′ | R′C(═O)— |
| R′ 3 SnX | SnR′ 3 |
| R′ 3 SiX | R′ 3 Si |
| R′ 2 (OR′)SiX or | SiR′ 2 (OR′) |
| (R′ 2 SiO) 3 |
Claims as granted
3 claimsLog in to read the claims of this application.
Log in to unlockClassifications
3 codes- C07F5/02
- C07C211/00
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.
Log in to unlock